August 31, 2014 6:13 AM ET

Biotechnology

Company Overview of Stellar Biotechnologies, Inc.

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, is engaged in the research, development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH), and related products and technologies to the therapeutic and diagnostic markets in the United States, Europe, and Asia. The company’s KLH is a high molecular weight (HMW) and immune-stimulating protein, which is used in cancers, infectious diseases, and immune disorders, as well as therapeutic vaccines for rheumatoid arthritis and Crohn's disease, systemic lupus erythematosus, lymphoma, metastatic breast cancer, prostate cancer, and other cancers and disorders. Its products include KLH pharmaceutical intermediates; HMW and sub...

332 East Scott Street

Port Hueneme, CA 93041

United States

Phone:

805-488-2800

Fax:

805-488-2889

Key Executives for Stellar Biotechnologies, Inc.

Chairman
Age: 63
Total Annual Compensation: $33.3K
Chief Financial Officer and Corporate Secretary
Age: 56
Total Annual Compensation: $137.5K
Chief Operations Officer
Age: 40
Total Annual Compensation: $155.8K
Chief Technology Officer
Age: 59
Total Annual Compensation: $155.8K
Compensation as of Fiscal Year 2013.

Stellar Biotechnologies, Inc. Key Developments

Stellar Biotechnologies, Inc. Announces Changing its Financial Year-End from August 31 to September 30

Pursuant to Section 4.8 of National Instrument 51-102 Continuous Disclosure Obligations, Stellar Biotechnologies, Inc. advised that it is changing its financial year-end from August 31 to September 30. Reason for the change is fiscal year and quarterly filings to coincide with calendar quarters. The transition year of the company will be the one month ended September 30, 2014.

Stellar Biotechnologies, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended May 31, 2014

Stellar Biotechnologies, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended May 31, 2014. For the quarter, the company reported total revenues of $102,581 compared to $73,214 for the same period a year ago. Net income and comprehensive income for the period was $1,813,290 or $0.02 per basic and diluted share compared to loss of $1,171,537 or $0.02 per basic and diluted share for the same period a year ago. Interest income was $16,583 against $1,075 a year ago. Stellar completed the NSF Phase IIB grant during the first quarter of 2014 and generated additional contract and commercial sales revenue during the second and third quarter. For the nine months, the company reported total revenues of $252,848 compared to $250,422 for the same period a year ago. Net loss and comprehensive loss for the period was $3,804,549 or $0.05 per basic and diluted share compared to $5,581,319 or $0.11 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $3,450,095 compared to $2,237,062 for the same period a year ago. Interest income was $43,223 against $3,708 a year ago. The decrease of $2.98 million in net loss for the third quarter of 2014, and cumulative decrease of $1.78 million net loss for the nine months ended May 31, 2014 were substantially affected by fluctuations in noncash change in fair value of warrant liability.

Stellar Biotechnologies, Inc. Announces Auditor Changes

Stellar Biotechnologies, Inc. announced that the resignation of D&H Group LLP, Chartered Accountants, on June 3, 2014, as auditor of the company be accepted, and Moss Adams LLP, Certified Public Accountants, be appointed as auditor of the company to be effective June 3, 2014, to hold office until the next annual meeting at a remuneration to be fixed by the directors.

Similar Private Companies By Industry

Company Name Region
Vitis Biosciences Inc. United States
MJ GeneWorks, Inc. United States
AMPRO Products, Inc. United States
Evivrus, Inc. United States
Giant Funding Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stellar Biotechnologies, Inc., please visit www.stellarbiotechnologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.